Evidence map›Paper›PMID 33995591›Full record

ReviewTherapeutic advances in medical oncology2021

Cell therapies in ovarian cancer.

Apostolos Sarivalasis, Matteo Morotti, Arthur Mulvey, Martina Imbimbo, George Coukos

Erratum issuedOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Therapeutic advances in medical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. CAR-T Cell Therapy in Ovarian Cancer: Where Are We Now?Diagnostics (Basel, Switzerland) · 2024
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Apostolos SarivalasisDepartment of Oncology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Matteo MorottiDepartment of Oncology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Arthur MulveyDepartment of Oncology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
Martina ImbimboDepartment of Oncology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
George CoukosCHUV, Rue du Bugnon 46, Lausanne BH09-701, Switzerland.
University of Lausanne · CHHôpital Orthopédique de la Suisse Romande · CHLudwig Cancer Research · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epithelial ovarian cancer (EOC) is the most important cause of gynecological cancer-related mortality. Despite improvements in medical therapies, particularly with the incorporation of drugs targeting homologous recombination deficiency, EOC survival rates remain low. Adoptive cell therapy (ACT) is a personalized form of immunotherapy in which autologous lymphocytes are expanded, manipulated

Indexed as

adoptive cell therapy (ACT)cancer immunotherapyneoantigensovarian cancertumor-infiltrating lymphocyte (TIL)

Identifiers

PMID33995591
PMCPMC8072818
OpenAlexW3158262036

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.